Trifluridine/tipiracil (FTD/TPI) can be used for several years as a ≥3rd line treatment in people with metastatic colorectal carcinoma (mCRC) and is also listed as a treatment option in the Dutch treatment guideline CRC. The QUALITAS study (a sub-study of PLCRC) now shows the effects on QoL of Dutch patients who have used Lonsurf®.
Based on data from 150 patients treated with Lonsurf® in daily practice, the QUALITAS study concludes that quality of life is maintained during treatment. In addition, the quality-of-life score at the start of treatment appears to be associated with survival time. Patricia Hamers and Mathijs Hendriks discuss the results in this article.